Retatrutide, developed under the code LY3437943, is arguably the most closely watched molecule in metabolic research. It is the first prominent triple receptor agonist: a single engineered peptide that activates the GLP-1, GIP, and glucagon receptors simultaneously.
What Retatrutide Is
Structurally, retatrutide is a modified peptide built on an incretin backbone with substitutions that confer activity at all three target receptors plus a fatty-acid modification for extended half-life. It represents the third generation of incretin-based design: single GLP-1 agonists came first, dual GIP/GLP-1 agonists second, and the triple agonist class extends the logic one receptor further.
Why Three Receptors
Each receptor contributes a distinct mechanism to the published pharmacology: GLP-1 receptor activation drives satiety signaling and glucose-dependent insulin response; GIP signaling adds a second incretin axis; and the glucagon component introduces an energy-expenditure dimension absent from earlier generations. The published phase 2 literature reported body weight reductions in the range of roughly 24% — figures that made the compound a landmark in the field and triggered enormous research interest in triple agonism as a design principle.
How Laboratories Study the Triple Agonist Class
Preclinical research uses retatrutide-class compounds to dissect multi-receptor pharmacology: receptor binding and potency panels, comparisons against single and dual agonists, and downstream studies of energy balance and glycemic signaling in model systems. The canonical comparison set spans all three generations — semaglutide-class, tirzepatide-class, and retatrutide-class — run side by side.
Research-Class Material
Pristine Aminos does not sell the pharmaceutical retatrutide. For laboratories studying this pathway, GLP3-R is our research-class triple agonist compound modeled on the retatrutide class — manufactured in the U.S., third-party tested to 99%+ purity, and supplied with a Certificate of Analysis for research use. It sits alongside the tirzepatide-class and semaglutide-class compounds in our GLP Receptor Agonists collection, and the class context is mapped in our guide to single, dual, and triple agonists.
All products referenced are intended strictly for in-vitro research and laboratory use only. They are not for human or veterinary use, consumption, or therapeutic application.